MG-ZG122
/ Mabgeek
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
September 05, 2026
Lessons learned from clinical trials of thymic stromal lymphopoietin (TSLP) inhibition.
(PubMed, J Allergy Clin Immunol)
- "Tezepelumab is currently the only approved anti-TSLP therapy. Other TSLP-targeting agents, including ecleralimab, SHR-1905, bosakitug, verekitug, sunakiment, TAVO101, ocankitug, HBM9378, MG-ZG122, GB-0895, and solrikitug, are in clinical development."
Journal • Review • Allergic Rhinitis • Allergy • Asthma • Atopic Dermatitis • Chronic Obstructive Pulmonary Disease • Chronic Rhinosinusitis With Nasal Polyps • Chronic Spontaneous Urticaria • Dermatitis • Dermatology • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis • Urticaria • IL13 • IL5 • TSLP
October 27, 2025
Safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of MG-ZG122, a long-acting humanized anti-thymic stromal lymphopoietin mAb, in healthy Chinese: a randomized, double-blind, placebo-controlled, dose-escalation, phase I study.
(PubMed, Expert Opin Investig Drugs)
- P1 | "MG-ZG122 was safe and well-tolerated with favorable PK profiles after a single SC injection in healthy Chinese at doses ranging from 52.5 to 420 mg, providing preliminary evidence for further evaluation. This study was registered with ClinicalTrials.gov, NCT05659927."
Clinical • Journal • P1 data • PK/PD data • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • TSLP
July 08, 2025
Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects
(clinicaltrials.gov)
- P2 | N=160 | Active, not recruiting | Sponsor: Shanghai Mabgeek Biotech.Co.Ltd
New P2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
February 23, 2024
Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=34 | Active, not recruiting | Sponsor: Shanghai Mabgeek Biotech.Co.Ltd | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2023 ➔ Mar 2024 | Trial primary completion date: Aug 2023 ➔ Jan 2024
Enrollment closed • Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
April 18, 2023
Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=34 | Recruiting | Sponsor: Shanghai Mabgeek Biotech.Co.Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • IL5
December 21, 2022
Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=34 | Not yet recruiting | Sponsor: Shanghai Mabgeek Biotech.Co.Ltd
New P1 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • IL5
1 to 6
Of
6
Go to page
1